Tendyne™ Transcatheter
Mitral Valve Implantation

QUALITY TIME
SECURED

.

Breakthrough therapy that can eliminate mitral regurgitation in select patients

Transcatheter mitral valve implantation (TMVI) is a breakthrough technology that offers select patients who have symptomatic, significant mitral regurgitation (≥ grade 3), a new option for safe and effective valve replacement. Tendyne TMVI is less invasive than conventional mitral valve surgery and provides symptom relief and quality of life improvement by eliminating MR.

  • Sustained MR elimination in 98% of patients at 1 year1
  • 96% technical success rate in minimally invasive procedure1,*
  • Exceptional safety profile1
  • Unique product design enabling repositioning and full retrievability intraprocedurally
  • Significant improvement in symptom and quality-of-life measures1
     

*Technical success per MVARC.



Tendyne Transcatheter
Mitral Valve Implantation

 

MAT-2000613 v2.0 | Item approved for OUS use only.

References
  1. Sorajja P, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol. 2019;73(11):1250-1260.
     

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

Sign up

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.